



Alexander L. Weis, Ph.D.  
President & CEO

Deutsche-Börse, Frankfurt, 10-11 July 2006

- » Company Highlights and History
- » Cancer Market Overview and The Opportunity
- » The Team - Management and Clinical Advisory Board
- » Business Strategy
- » Pipeline and Portfolio
- » IP Strategy
- » Summary

# Company Highlights

- » Large, growing market with significant ***unmet needs***
- » Significant opportunity for ***targeted therapeutics***
- » Very ***experienced team*** - management and clinical advisory board
- » ***Focused, disciplined*** approach
- » ***Promising*** pipeline
- » ***Comprehensive, sound*** IP Position

- » 3<sup>rd</sup> Q 2004 - - Founding of OncoVista
- » 4<sup>th</sup> Q 2004 - - In-licensing of L-Nucleoside Conjugate and Tubulin Isotype-Specific Anti-Mitotic technologies
- » 1<sup>st</sup> Q 2005 - - Clinical Advisory Board established
- » 2<sup>nd</sup> Q 2005 - - Facility leased and occupied
- » 4<sup>th</sup> Q 2005 - - Acquired majority control of AdnaGen AG & \$4.4M raise
- » 1<sup>st</sup> Q 2006 - - Acquired Aengus (& Cordycepin) & \$1.7M raise
- » 2<sup>nd</sup> Q 2006 - - Phase II in-licensing and diagnostic partnership term sheets

- » Cancer is the **second leading cause of death** in the US after heart disease
- » **11 million new cases** are diagnosed each year globally; this figure is expected to increase to **16 million** annually by 2020
- » In 2005, one American died **every 60 seconds from cancer**
- » The 2005 worldwide (WW) market for cancer drugs exceeded **\$60 billion** and is expected to double in the next 5 years; US is approx. one-half the WW market
- » Despite an increase in the number and types of treatments available, **many types and stages of cancer remain poorly treated**
- » Inability of most **chemotherapy** treatments to differentiate between healthy and cancerous cells **causes severe damage to healthy tissues and adverse side effects**
- » **Metastatic cancer** presents the **greatest mortality risk** to the patient

# Why OncoVista?

OncoVista's mission is the development and rapid commercialization of innovative targeted therapies for safe and efficacious treatment of cancer and other life threatening diseases.

# ▶ The Team - Management

- **Alexander L. Weis, Ph.D.:** Chairman, CEO & President
  - Principal founder of OncoVista, Inc.
  - 20+ years of executive and principal scientific experience in bio-pharma and chemistry
  - Over 60 publications and 30 patents
  - Previous Experience
    - 1994-1998: Co-founder of ILEX Oncology, Chief Scientific Officer and Executive VP
    - Earlier: Lipitek International, Vector Therapeutics, MykoBiologics, Cancer Therapy and Research Center, Sterling Drugs and the Eastman Kodak Company
- **Robert Patterson, M.B.A.:** Director of Finance and Human Resources
  - 20+ years of experience in corporate financial management
  - Previous Experience
    - Bausch & Lomb, Lipitek International, and Mission Technologies
- **Corey Levenson, Ph.D. :** Chief Technology Officer
  - 20+ years of experience in the biotechnology and pharmaceutical industries
  - Previous Experience
    - Roche Molecular Systems, Cetus Corporation, ILEX Oncology
  - Ph.D. in Pharmaceutical Chemistry from UCSF
- **J. Kay Noel, Ph.D.:** Director of Regulatory Affairs
  - 20+ years of experience in technology assessment, drug development and implementation of regulatory strategies
  - Previous Experience
    - Cetus Corporation, Alpha Therapeutics, and Abbott Biologics

# The Team


## Clinical Advisory Board

- **Eric Rowinsky, M.D. (Chairman)**
  - Senior VP and Chief Medical Officer at ImClone Systems, Inc.
  - 20 + years of experience in oncology drug development
  - Over 700 publications, abstracts and book chapters
  - Key roles in the development of Taxol®, Hycamtin® and many other anticancer drugs
- **Esteban Cvitkovic, M.D.**
  - Chairman of Cvitkovic & Associés Consultants S.A.
  - 20+ years of experience in oncology therapeutics
  - Authored more than 160 peer-reviewed articles and 450 abstracts on oncology
  - Key roles in development and registration of oxaliplatin, docetaxel, CPT-11 and iriffulven
- **Randall K. Johnson, Ph.D.**
  - Senior advisor to pharma industry
  - 20+ years experience in cellular-based markers and cell regulation
  - Authored over 200 scientific papers and awarded 14 patents
  - Senior positions at GSK and NCI
- **Allan M. Green, M.D., Ph.D., J.D.**
  - Senior advisor to industry
  - 20+ years experience as an expert in FDA regulatory matters and business strategy to the pharmaceutical industry
  - Authored over 50 peer-review articles and holds 6 US patents
  - Board certified in Internal and Nuclear Medicine


## Clinical Advisory Board (Cont'd)

- **Ronald P. McCaffrey, M.D.**
  - On staff at Harvard Medical School and Massachusetts General Hospital
  - 20+ years experience in hematologic oncology
  - Authored over 90 peer-review articles and abstracts plus co-edited two books
  - SVP at the Intn'l Assoc. for Comparative Research on Leukemia and Related Diseases
- **Pedro Santabarbara, M.D., Ph.D.**
  - Senior Director of Clinical Development at PHARMA MAR S.A.
  - 20+ years experience in oncology drugs
  - Authored over 80 articles and abstracts in the field of oncology
  - Key roles in development of Taxol®, Taxotere®, Campath® and most recently Tarceva®
- **Marcel Rozenzweig, M.D.**
  - Senior VP of Drug Development at GPC-Biotech
  - 20+ years of experience in oncology and immunology
  - Authored and co-authored more than 200 scientific publications
  - Key roles in commercialization of 11 drugs including Taxol® and Paraplatin®

- » **A Focused In-licensing / Acquisition Program for Drugs in Clinical Trials**
  - » Many shelved drug products are available, due to loss of internal sponsorship, perceived lack of market size, or overcrowded pipeline
  - » During 2005, OncoVista evaluated over 30 in-licensing opportunities, of which 4 are being pursued, two of them very actively
- » **A Practical, Rational Approach to Drug Development**
  - » Craft clinical development and registration strategies that focus on potential for accelerated approach and/or orphan status
  - » Focus effort in registration success, therapeutic effectiveness and sound pharma -economics
- » **A Disciplined Internal Development Strategy for Therapeutics**
  - » Cordycepin
  - » L-Nucleoside Conjugate
  - » Tubulin Isotype-Specific Anti-Mitotics
- » **An Integrated Diagnostics Strategy**
  - » Proprietary diagnostic platform to help target responsive patients
  - » Diagnosis, treatment and prognosis based on monitoring of disease progression




Systemic challenges



Tumor-specific challenges

# Our Pipeline


- » A focus on registration efficiency through accelerated approval and / or orphan status
- » OncoVista shortly expects to supplement the in-house pipeline with at least one in-licensed compound in advanced Phase II development



\*Marketed in Europe; Seeking FDA approval in 2007

- » Term sheet signed with OSI for in-licensing of OSI-7904L, a Phase II drug candidate (as of June 2006)
- » OSI-7904L is a liposome encapsulated formulation of OSI-7904, the most potent thymidylate synthase inhibitor (TSI)
- » OSI-7904L has been tested in several Phase II studies and has demonstrated anti-tumor activity as a single agent in gastric/gastroesophageal junction cancer
- » The market potential for OSI-7904L is \$400-600M worldwide for gastrointestinal cancers and could exceed \$1 billion worldwide if its use was expanded to treat patients with metastatic breast and head & neck cancers.

# ▶ Our Portfolio-Cordycepin



- » Obtained through OncoVista's merger with Aengus Pharmaceuticals, LLC
- » Effectively treats TdT-positive ALL and CML, as well as high-grade lymphoblastic lymphoma
- » The market size for this drug is projected to be potentially \$1+ billion
- » The Company will be submitting an Investigational New Drug application ("IND") for the Phase I/II trials for refractory TdT-positive leukemia


# Our Portfolio - Cordycepin

- » In 2005 in the US: **35,000** new leukemia cases, **200,000** individuals living with or in remission from leukemia, annual morbidity rate of **23,000**
- » **Cordycepin** is a treatment for leukemia patients that are refractory to chemotherapeutics or have experienced a relapse
- » Relies upon the presence of terminal deoxynucleotidyl transferase (“TdT”) for its therapeutic activity
- » TdT is expressed in certain patients with acute lymphocytic leukemia (“ALL”); acute myelogenous leukemia (“AML”); and chronic myelogenous leukemia (“CML”)
- » The table below represents potential addressable patient populations for the US


	<b>A.L.L.</b>	<b>A.M.L.</b>	<b>C.M.L.</b>	<b>Total</b>
Overall Annual Incidence	4,000	12,000	4,600	20,600
Patient Prevalence Multiple Factor	3x	3x	10x	-
Patient Prevalence	12,000	36,000	46,000	82,720
% TdT-Positive Patients	95%	10%	10%	-
TdT-Positive Patient Prevalence	11,400	3,600	4,600	19,600
Overall Five-Year Survival Rate	65%	20%	32%	-

- Additional 1,000 TdT positive patients suffering from lymphoblastic lymphoma could be added to approximately **20,000** addressable adults from the table



- » Colorectal cancer is the third most common form of cancer
- » For 2005: **145,000** new colorectal cancer cases of which colon cancer accounts for **105,000**; colorectal cancer caused **56,000** deaths
- » While colon cancer has 90% curative rate at an early stage detection, 40 to 50% develop metastatic disease, of which as many as 50 to 60% ultimately die from it or from a recurrence
- » **L-nucleoside conjugates** target cancerous cells, resulting in **less toxic** and **more efficacious** treatment
- » A potential clinical candidate for the treatment of colon cancer, with demonstrated efficacy in treatment of breast and prostate cancers
- » Anticipated IND filing in first quarter of 2007



### HT-29 Tumor Growth Inhibition




This graph shows the ability of OVI-117 to inhibit growth of human colon tumor (HT-29) xenograft growing in a mouse model



Microtubules play an essential role in cellular replication and proliferation

Binding site modeling enables *in silico* screening of large chemical libraries and facilitates rational drug design of novel anti-mitotics



Drug companies with large libraries of taxanes are being approached to conduct *in silico* screening using the OncoVista database.

## Tubulin Isotype-Specific Anti-Mitotics

- » Proprietary database of **500** different tubulin structures
- » Basis of new cancer treatments that target microtubule isotypes specific to cancers
- » Small amount of a drug can “poison” a microtubule, thereby **inhibiting the cancerous cell division** and further growth
- » **Limited side effects**, as targeted isotypes occur in few healthy cells, allowing high therapeutic doses with minimized associated toxicity
- » First compound designed and synthesized ( $\alpha\beta_{VI}$  isotype)
- » **By the end of 2006**, OncoVista expects to **select several candidates** for detailed study in the lab

- » Tubulin isotype compositions vary by cell type
- » Cancer cells express isotypes whose distribution in normal tissues is rare
- » Drug sensitivity and resistance are isotype-dependent
- » The difference between tubulin isotypes has been identified, and enables isotype-specific therapies

## Mammalian $\beta$ -Tubulin Isotypes

<u>Isotype</u>	<u>Distribution</u>
$\beta_I$	Most cells
$\beta_{II}$	Neurons, glia, inner ear, skeletal muscle, smooth muscle
$\beta_{III}$	Neurons, Sertoli cells, colon
$\beta_{IVa}$	Neurons and glia
$\beta_{IVb}$	Most tissues
$\beta_V$	Uterine, adenocarcinoma
$\beta_{VI}$	Platelets, marrow, spleen
$\beta_{VII}$	Brain

# Acquisition of AdnaGen AG




OncoVista has acquired controlling interest in AdnaGen AG, a German company that has developed proprietary technology for the detection of circulating tumor cells (CTCs)

- » Historically, detection and staging of tumors has been based upon determination of size and, more recently, by using imaging technologies (CAT scans, MRI, etc.)
  - » Limited to characterization of primary tumors which are above 0.5 to 1 cm in cross section
- » AdnaGen technology allows sensitive detection of malignant circulating tumor cells in the blood regardless of whether or not a primary tumor is detected


## 1) Immunomagnetic cell enrichment

Tumor cell enrichment using magnetic particles conjugated with an antibody mixture.




## 2) mRNA isolation & RT

mRNA stabilization, mRNA isolation with oligo(dT) magnetic beads and cDNA synthesis by reverse transcription.



## 3) Multiplex-PCR

Expression analysis of tumor associated markers.



- » Early detection of metastatic tumor cells can mean the difference between life and death in certain instances
- » Most methods used for cancer staging have comparatively low detection sensitivity
- » Physicians and patients make treatment decisions often based on subjective and qualitative information
- » Ability to detect tumor markers quantitatively would improve treatment process in two ways:
  - » Enable early disease diagnosis or relapse and residual disease
  - » Ability to stratify patients into groups most likely to respond to a therapy, eliminating unnecessary side effects from the treatments that would provide no benefit
- » OncoVista/AdnaGen proprietary technology detects the low number of circulating cancer cells, allowing diagnosis very early in metastatic process
- » **95+% likelihood of detecting 2 circulating tumor cells per 5ml of blood (< 1ppm)**
- » Advantages of the technology:
  - » Novel and highly sensitive detection of circulating tumor cells
  - » Early detection of metastatic cancer
  - » Monitoring of treatment efficacy
  - » Selection and stratification of clinical trial participants

- » Augment existing patent position with new domestic and international applications
  - » Currently **11 U.S. and foreign patents** issued
  - » Over **two dozen applications filed** in the U.S. and abroad
- » Expand patent protection on portfolio to **other areas of IP (i.e., trademarks, copyright, know-how)** where appropriate
- » Enhance existing in-house capability through the **in-licensing of the rights** to related / complementary technologies

## ▸ Financing History

- The Company has funded its operations primarily through proceeds from the sale of:
  - \$0.6 million in common stock in start-up financing in 2004
  - \$4.4 million in common stock in 2005 (some carried over into 2006)
  - \$1.7 million in common stock to OncoVentures in March 2006

- » OncoVista does not intend to develop sales and marketing capabilities – we'll rely on strategic partnerships.
- » The company will realize revenues through licensing/milestone fees and royalties.

## Financial Outlook

- » OncoVista is currently raising \$15 million in institutional financing for:
  - » Operating expenses
  - » In-licensing of Phase II and Phase I drugs
- » OncoVista expects to be publicly traded in 2007

